Patents Assigned to Amazentis SA
  • Patent number: 12220424
    Abstract: A composition comprising: a) nicotinamide riboside and b) a urolithin which is a compound of formula (I) or a salt thereof: wherein: A, B, C and D are each independently selected from H and OH; W, X and Y are each independently selected from H and OH; and Z is selected from H and OH. The compositions are useful as medicaments, for example for treating muscle-related pathological conditions, neurodegenerative diseases, and/or mitochondrial diseases and as dietary supplements, functional foods and beverages, and specialised nutrition or medical foods.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: February 11, 2025
    Assignee: Amazentis SA
    Inventors: Penelope Andreux, Christopher L. Rinsch
  • Patent number: 12109190
    Abstract: Disclosed are compounds for use in raising an immune response to an antigen and/or enhancing, modulating or augmenting an immune response to an antigen. Particularly the use of urolithins. The invention also relates to immune enhancers comprising urolithins, methods of using such immune enhancers and processes for the preparation of such immune enhancers. The invention also relates to the use of urolithins in methods for modulating stem cell function, for example, enhancing stem cell numbers, promoting stem cell regeneration and promoting stem cell differentiation.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: October 8, 2024
    Assignee: Amazentis SA
    Inventors: Anurag Singh, Davide D'Amico, Penelope Andreux, William Blanco-Bose, Christopher L. Rinsch
  • Patent number: 12036205
    Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: July 16, 2024
    Assignee: Amazentis SA
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Charles Thomas, Carmen Sandi, Johan Auwerx, Penelope Andreux, Richardus Houtkooper, Eija Pirinen, Laurent Mouchiroud, David Genoux
  • Patent number: 12030863
    Abstract: The invention provides compounds of formula (I) or salts thereof: wherein: A, B, C, D, W, X, Y and Z are as defined in the specification, and at least one of A, B, C, D, W, X, Y and Z is OR1; each R1 being independently H or C(?O)R2, and at least one R1 group being C(?O)R2; where each R2 is selected from: CHR3NHR4, where R4 is H and R3 is a group selected from CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, CH2Ph, CH2-3-(1H-indole), CH2CH2SCH3, CH2OH, CHOHCH3, CH2SH, CH2SeH and CH2PhpOH, wherein said R3 group can optionally be substituted by one or more groups selected from halogen, cyano, nitro, ORA or C1-C4 alkyl; or R3 and R4 together with the C and N atoms to which they are attached form a 5-membered heteroalkyl ring, wherein said heteroalkyl ring can optionally be substituted by one or more groups selected from halogen, cyano, nitro, ORA or C1-C3 alkyl, wherein RA is C1-C4 alkyl optionally substituted with one or more halogen, cyano or nitro groups.
    Type: Grant
    Filed: November 2, 2021
    Date of Patent: July 9, 2024
    Assignee: Amazentis SA
    Inventors: Christopher L. Rinsch, Rune Andreas Ringom
  • Patent number: 11969408
    Abstract: The invention provides a compound of formula (I) wherein: A, B, C, D, W, X, Y and Z are each independently selected from H and OH; or a salt thereof; for use in the treatment and/or prophylaxis of a condition, disease or disorder in a subject, wherein the compound or salt is orally administered to a subject in a daily amount of from 2.8 to 6.6 mmol per day, over a period of at least 21 days. Also are provided are the compound of formula (I) for use in increasing mitophagy and/or autophagy, maintaining and/or improving muscle function and administration as a dietary, nutritional and/or health supplement.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: April 30, 2024
    Assignee: Amazentis SA
    Inventors: Christopher Rinsch, Penelope Andreux, Anurag Singh
  • Patent number: 11931335
    Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: March 19, 2024
    Assignee: Amazentis SA
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
  • Patent number: 11931336
    Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: March 19, 2024
    Assignee: Amazentis SA
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
  • Patent number: 11925616
    Abstract: The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition.
    Type: Grant
    Filed: May 5, 2022
    Date of Patent: March 12, 2024
    Assignee: Amazentis SA
    Inventors: Penelope Andreux, Christopher Rinsch, William Blanco-Bose
  • Patent number: 11903922
    Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: February 20, 2024
    Assignee: Amazentis SA
    Inventors: Christopher Rinsch, William Blanco-Bose, Bernard Schneider, Charles Thomas, Carmen Sandi, Johan Auwerx, Penelope Andreux, Richardus Houtkooper, Eija Pirinen, Laurent Mouchiroud, David Genoux
  • Patent number: 11878964
    Abstract: The invention provides compositions comprising a source of protein and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition. The invention also provides kits comprising urolithin and protein.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: January 23, 2024
    Assignee: Amazentis SA
    Inventors: Penelope Andreux, Christopher L. Rinsch, William Blanco-Bose
  • Patent number: 11634401
    Abstract: Disclosed are methods for preparing a salt of urolithin A and, in turn, urolithin A. The methods are advantageous for the large-scale preparation of urolithin A or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: April 25, 2023
    Assignee: Amazentis SA
    Inventors: Wolfgang Skranc, George Yiannikouros, Alexander Trofimov, Zhixing Shan, Christopher Goss
  • Patent number: 11426380
    Abstract: Disclosed are compounds for use in raising an immune response to an antigen and/or enhancing, modulating or augmenting an immune response to an antigen. Particularly the use of urolithins. The invention also relates to immune enhancers comprising urolithins, methods of using such immune enhancers and processes for the preparation of such immune enhancers. The invention also relates to the use of urolithins in methods for modulating stem cell function, for example, enhancing stem cell numbers, promoting stem cell regeneration and promoting stem cell differentiation.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: August 30, 2022
    Assignee: Amazentis SA
    Inventors: Anurag Singh, Davide D'Amico, Penelope Andreux, William Blanco-Bose, Christopher L. Rinsch
  • Patent number: 11337957
    Abstract: The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: May 24, 2022
    Assignee: Amazentis SA
    Inventors: Penelope Andreux, Christopher Rinsch, William Blanco-Bose
  • Patent number: 11234960
    Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: February 1, 2022
    Assignee: Amazentis SA
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Charles Thomas, Carmen Sandi, Johan Auwerx, Penelope Andreux, Richardus Houtkooper, Eija Pirinen, Laurent Mouchiroud, David Genoux
  • Patent number: 11180468
    Abstract: The invention provides compounds of formula (I) or salts thereof: wherein: A, B, C, D, W, X, Y and Z are as defined in the specification, and at least one of A, B, C, D, W, X, Y and Z is OR1; each R1 being independently H or C(?O)R2, and at least one R1 group being C(?O)R2; where each R2 is selected from: CHR3NHR4, where R4 is H and R3 is a group selected from CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, CH2Ph, CH2-3-(1H-indole), CH2CH2SCH3, CH2OH, CHOHCH3, CH2SH, CH2SeH and CH2PhpOH, wherein said R3 group can optionally be substituted by one or more groups selected from halogen, cyano, nitro, ORA or C1-C4 alkyl; or R3 and R4 together with the C and N atoms to which they are attached form a 5-membered heteroalkyl ring, wherein said heteroalkyl ring can optionally be substituted by one or more groups selected from halogen, cyano, nitro, ORA or C1-C3 alkyl, wherein RA is C1-C4 alkyl optionally substituted with one or more halogen, cyano or nitro groups.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: November 23, 2021
    Assignee: Amazentis SA
    Inventors: Christopher Rinsch, Rune A. Ringom
  • Patent number: 11166972
    Abstract: Disclosed are compositions comprising nicotinamide riboside and a urolithin. The compositions are useful as medicaments, for example, for treating muscle-related pathological conditions, neurodegenerative diseases, and/or mitochondrial diseases, and as dietary supplements, functional foods and beverages, and as specialized nutrition or medical foods.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: November 9, 2021
    Assignee: Amazentis SA
    Inventors: Penelope Andreux, Christopher L. Rinsch
  • Patent number: 11166937
    Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: November 9, 2021
    Assignee: Amazentis SA
    Inventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Charles Thomas, Carmen Sandi, Johan Auwerx, Penelope Andreux, Richardus Houtkooper, Eija Pirinen, Laurent Mouchiroud, David Genoux
  • Patent number: 11020373
    Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: June 1, 2021
    Assignee: Amazentis SA
    Inventors: Christopher Lawrence Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
  • Patent number: 10988453
    Abstract: The invention provides compositions comprising a source of protein and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition. The invention also provides kits comprising urolithin and protein.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: April 27, 2021
    Assignee: Amazentis SA
    Inventors: Penelope Andreux, Christopher L. Rinsch, William Blanco-Bose
  • Patent number: 10906883
    Abstract: Disclosed are methods for preparing a salt of urolithin A and, in turn, urolithin A. The methods are advantageous for the large-scale preparation of urolithin A or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: February 2, 2021
    Assignee: Amazentis SA
    Inventors: Wolfgang Skranc, George Yiannikouros, Alexander Trofimov, Zhixing Shan, Christopher Goss